Healthline - Dr. Ashutosh K. Tewari: “Men with Metastatic Prostate Cancer Live Longer When Given Chemo First”

 – June 2, 2014  –– 

A new study finds that men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they had received a chemotherapy drug as initial treatment, instead of waiting for the disease to become resistant to hormone-blockers, suggesting a new standard of treatment for such patients is viable. "The early results from this NIH funded study provide strong evidence to support the utilization of docetaxel along with ADT in high volume metastatic prostate cancer patients,” said Ashutosh K. Tewari, MB, BS, Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai. Learn more